Optimization of time to initial vancomycin target trough improves clinical outcomes

SpringerPlus

Volumn 4, Issue 1, 2015, Pages

  Cardile, Anthony P ^a   Tan, Christopher ^a   Lustik, Michael B ^a   Stratton, Amy N ^a   Madar, Cristian S ^a   Elegino, Jun ^a   Hsue, Günther ^a  

^a TRIPLER ARMY MEDICAL CENTER   (United States)

Author keywords

MRSA; TDM; Trough; Vancomycin

Indexed keywords

EID: 84937873304     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/s40064-015-1146-9     Document Type: Article

References (56)

1. American Thoracic Society; Infectious Diseases Society of America (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171:388–416
2. Aubron C, Corallo CE, Nunn MO, Dooley MJ, Cheng AC (2011) Evaluation of the accuracy of a pharmacokinetic dosing program in predicting serum vancomycin concentrations in critically ill patients. Ann Pharmacother 45:1193–1198
3. Barenfanger J, Short MA, Groesch AA (2001) Improved antimicrobial interventions havebenefits. J Clin Microbiol 39:2823–2828
4. Boissinot M, Bergeron MG (2002) Toward rapid real-time molecular diagnostic to guide smart use of antimicrobials. Curr Opin Microbiol 5:478–482
5. Bond CA, Raehl CL (2005) Clinical and economic outcomes of pharmacist-managed aminoglycoside or vancomycin therapy. Am J Health Syst Pharm 62:1596–1605
6. Burgess LD, Drew RH (2014) Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy 34:670–676
7. Centers for Disease Control and Prevention (CDC) (2004) Community-associated methicillin-resistant Staphylococcus aureus infections in Pacific Islanders-Hawaii, 2001–2003. MMWR Morb Mortal Wkly Rep 27:767–770
8. Clemens EC, Chan JD, Lynch JB, Dellit TH (2011) Relationships between vancomycin minimum inhibitory concentration, dosing strategies, and outcomes in methicillin-resistant Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis 71:408–414
9. Corallo CE, Nunn MO, Dooley MJ, Cheng AC (2011) Evaluation of the accuracy of a pharmacokinetic dosing program in predicting serum vancomycin concentrations in critically ill patients. Ann Pharmacother 45:1193–1198
10. Crowley RK, Fitzpatrick F, Solanki D, FitzGerald S, Humphreys H, Smyth EG (2007) Vancomycin administration: the impact of multidisciplinary interventions. J Clin Pathol 60:1155–1159
11. Davis SL, Scheetz MH, Bosso JA, Goff DA, Rybak MJ (2013) Adherence to the 2009 consensus guidelines for vancomycin dosing and monitoring practices: a cross-sectional survey of US hospitals. Pharmacotherapy 33:1256–1263
12. Fernández de Gatta MD, Calvo MV, Hernández JM, Caballero D, San Miguel JF, Domínguez-Gil A (1996) Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies. Clin Pharmacol Ther 60:332–340
13. Gawronski KM, Goff DA, Brown Jack, Khadem TM, Bauer KA (2013) A stewardship program’s retrospective evaluation of vancomycin AUC24/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. Clin Ther 35:772–779
14. Golenia BS, Levine AR, Moawad IM, Yeh DD, Arpino PA (2013) Evaluation of a vancomycin dosing nomogram based on the Modification of Diet in Renal Disease equation in intensive care unit patients. J Crit Care 28:710–716
15. Hall WH, Ramachandran R, Narayan S, Jani AB, Vijayakumar S (2004) An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer 4:94
16. Hall RG 2nd, Giuliano CA, Haase KK, Hazlewood KA, Frei CR, Forcade NA et al (2012) Empiric guideline-recommended weight-based vancomycin dosing and mortality in methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study. BMC Infect Dis 12:104
17. Halm EA, Fine MJ, Marrie TJ (1998) Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 279:1452–1457
18. Hazlewood KA, Brouse SD, Pitcher WD, Hall RG (2010) Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? Am J Med 123:182–187
19. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A (2006) High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 166:2138–2144
20. Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O’Sullivan MV et al (2013) Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 57:1654–1663
21. Hoste EA, Clermont G, Kersten A, Venkataraman R, Angus DC, De Bacquer D et al (2006) RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care 10:R73
22. Iwamoto T, Kagawa Y, Kojima M (2003) Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin. Biol Pharm Bull 26:876–879
23. Jacob JT, DiazGranados CA (2013) High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis. Int J Infect Dis 17:e93–e100
24. Jarvis WR, Jarvis AA, Chinn RY (2012) National prevalence of methicillin-resistant Staphylococcus aureus in inpatients at United States health care facilities, 2010. Am J Infect Control 40:194–200
25. Jeffres MN, Isakow W, Doherty JA, McKinnon PS, Ritchie DJ, Micek ST et al (2006) Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 130:947–955
26. Klein E, Smith DL, Laxminarayan R (2007) Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999–2005. Emerg Infect Dis 13:1840–1846
27. Kullar R, Leonard SN, Davis SL, Delgado G Jr, Pogue JM, Wahby KA et al (2011a) Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15–20 mg/L suggested by the vancomycin consensus guidelines. Pharmacotherapy 31:441–448
28. Kullar R, Davis SL, Levine DP, Rybak MJ (2011b) Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 52:975–981
29. Kullar R, Davis SL, Taylor TN, Kaye KS, Rybak MJ (2012) Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort. Pharmacotherapy 32:195–201
30. Kumar A, Haery C, Paladugu B, Kumar A, Symeoneides S, Taiberg L et al (2006) The duration of hypotension before the initiation of antibiotic treatment is a critical determinant of survival in a murine model of Escherichia coli septic shock: association with serum lactate and inflammatory cytokine levels. J Infect Dis 193:251–258
31. Leu WJ, Liu YC, Wang HW, Chien HY, Liu HP, Lin YM (2012) Evaluation of a vancomycin dosing nomogram in achieving high target trough concentrations in Taiwanese patients. Int J Infect Dis 16:e804–e810
32. Li J, Udy AA, Kirkpatrick CM, Lipman J, Roberts JA (2012) Improving vancomycin prescription in critical illness through a drug use evaluation process: a weight-based dosing intervention study. Int J Antimicrob Agents 39:69–72
33. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL (2009) Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 49:507–514
34. McCluggage L, Lee K, Potter T, Dugger R, Pakyz A (2010) Implementation and evaluation of vancomycin nomogram guidelines in a computerized prescriber-order-entry system. Am J Health Syst Pharm 67:70–75
35. Minejima E, Choi J, Beringer P, Lou M, Tse E, Wong-Beringer A (2011) Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients. Antimicrob Agents Chemother 55:3278–3283
36. Minne L, Eslami S, Kuiper RA, Abu-Hanna A, Dongelmans DA (2012) Five years of therapeutic drug monitoring in the intensive care did not change vancomycin prescription behaviour: perceived needs for decision support. Minerva Anestesiol 78:684–692
37. Morrison AP, Melanson SE, Carty MG, Bates DW, Szumita PM, Tanasijevic MJ (2012) What proportion of vancomycin trough levels are drawn too early?: frequency and impact on clinical actions. Am J Clin Pathol 137:472–478
38. Nunn MO, Corallo CE, Aubron C, Poole S, Dooley MJ, Cheng AC (2011) Vancomycin dosing: assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software. Ann Pharmacother 45:757–763
39. Patanwala AE, Norris CJ, Nix DE, Kopp BJ, Erstad BL (2009) Vancomycin dosing for pneumonia in critically ill trauma patients. J Trauma 67:802–804
40. Pea F, Furlanut M, Negri C, Pavancomycin F, Crapis M, Cristini F et al (2009) Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycincomycin administered by continuous infusion in critically ill patients. Antimicrob Agents Chemother 53:1863–1867
41. Revilla N, Martín-Suárez A, Pérez MP, González FM, de Gatta Fernández, Mdel M (2010) Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation. Br J Clin Pharmacol 70:201–212
42. Rosini JM, Laughner J, Levine BJ, Papas MA, Reinhardt JF, Jasani NB (2015) A randomized trial of loading vancomycin in the emergency department. Ann Pharmacother 49:6–13
43. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M et al (2009) Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66:82–98
44. Rybak MJ, Vidaillac C, Sader HS, Rhomberg PR, Salimnia H, Briski LE et al (2013) Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: comparison of Etest and three automated testing methods. J Clin Microbiol 51:2077–2081
45. Safdar N, Maki DG (2002) The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 136:834–844
46. Sánchez GM (2009) Early antibiotic treatment failure. Int J Antimicrob Agents 34:S14–S19
47. Shen WC, Chiang YC, Chen HY, Chen TH, Yu FL, Tang CH et al (2011) Nephrotoxicity of vancomycin in patients with methicillin-resistant Staphylococcus aureus bacteraemia. Nephrology (Carlton) 16:697–703
48. Steinmetz T, Eliakim-Raz N, Goldberg E, Leibovici L, Yahav D (2015) Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis. Clin Microbiol Infect 21:665–673
49. Stryjewski ME, Szczech LA, Benjamin DK Jr, Inrig JK, Kanafani ZA, Engemann JJ et al (2007) Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 44:190–196
50. Swartling M, Gupta R, Dudas V, Guglielmo BJ (2012) Short term impact of guidelines on vancomycin dosing and therapeutic drug monitoring. Int J Clin Pharm 34:282–285
51. Traugott KA, Maxwell PR, Green K, Frei C, Lewis JS 2nd (2011) Effects of therapeutic drug monitoring criteria in a computerized prescriber-order-entry system on the appropriateness of vancomycin level orders. Am J Health Syst Pharm 68:347–352
52. Truong J, Levkovich BJ, Padiglione AA (2012) Simple approach to improving vancomycin dosing in intensive care: a standardised loading dose results in earlier therapeutic levels. Intern Med J 42:23–29
53. Vandecasteele SJ, De Vriese AS (2010) Recent changes in vancomycin use in renal failure. Kidney Int 7:760–764
54. Welty TE, Copa AK (1994) Impact of vancomycinn therapeutic drug monitoring on patient care. Ann Pharmacother 28:1335–1339
55. Winter Michael E (2003) Basic clinical pharmacokinetics. Wolters Kluwer/Lippincott Williams & Wilkins Health, Philadelphia
56. Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A et al (2012) Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 54:621–629